Centessa Pharmaceuticals plc announced the appointment of Harris L. Rotman, PhD, as Senior Vice President, Regulatory Affairs. Prior to joining Centessa, Dr. Rotman served as Senior Vice President, Head of Regulatory Affairs at SwanBio Therapeutics, where he was responsible for managing the company's neuromuscular disease gene therapy programs. Dr. Rotman also previously served as Vice President, Head of Regulatory Affairs, Branded Business at Endo Pharmaceuticals where he led the branded global regulatory affairs department in the US and Ireland. Earlier in his career, Dr. Rotman held executive regulatory leadership roles with Indivior, Shire Pharmaceuticals, Sanofi and Wyeth Pharmaceuticals.

Dr. Rotman earned his PhD in Microbiology and Molecular Virology from Thomas Jefferson University, and a BS in Biological Sciences from Cook College at Rutgers University.